Erkim Announces the Establishment of Erkim Labs as its R&D arm
Erkim today announces the establishment of Erkim Labs Research and Development A.S. as it's subsidiary wholly focused on research and development of novel therapies targeting unmet needs in rare and hematological diseases.
The company will immediately start the research and development activities on two undisclosed pre-clinical biotechnology assets. The company will have it's own staff in addition to strategic partnerships with local universities to bolster academia and industry collaboration in the country.
Cem Zorlular, CEO of Erkim commented "Our corporate strategy is to keep investing on innovation to have Turkey play a strategic role in global pharmaceutical industry. We truly believe, with the right strategy, an globally accepted reference product discovered and developed in Turkey is possible."